Stocktoria
Alector, Inc. ALEC
Alector, Inc. (ALEC) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $21.0M at a -679.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.672 |
| Retained earnings / assets | -3.315 |
| EBIT / assets | -0.532 |
| Equity / liabilities | 0.117 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALEC | Alector, Inc. | 1/9 | -9.85 | — | -79.1% |
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
| MGX | Metagenomi Therapeutics, Inc. | 1/9 | -0.61 | — | -51.8% |
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
About Alector, Inc.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
FAQ
Is ALEC financially healthy?
Alector, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ALEC pay a dividend?
No, Alector, Inc. does not currently pay a dividend.
How profitable is ALEC?
In FY2025, Alector, Inc. had a net margin of -679.2% and a return on equity of -466.3%.
What is the analyst price target for ALEC?
The average Wall-Street price target for Alector, Inc. is $3.10, about 44.2% above the recent price, from 5 analysts.
Is ALEC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Alector, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.